论文部分内容阅读
探讨替尼泊甙 (VM -2 6 )联合中剂量阿糖胞苷 (Ara -C)治疗难治和复发急性白血病的疗效及不良反应。方法 对 2 2例难治和复发性急性白血病用替尼泊甙 10 0mg ,静脉滴注 ,第 1～ 3d ,Ara -C 0 .5～ 1.0gq12h ,第 1～ 3d ,观察其疗效及不良反应并随访。结果 完全缓解 10例 ,完全缓解率 45 % ;部分缓解 3例 ,部分缓解率 13 6 % ;总有效率 5 8 6 %。持续缓解时间 3～ 12个月。骨髓抑制发生率 10 0 %。结论 VM -2 6联合中剂量Ara -C治疗难治和复发急性白血病临床可取得较好疗效 ,VM -2 6疗效优于VP-16 ,中剂量Ara -C毒副作用较大剂量Ara -C相对较小 ,大部分病人可以耐受。
To investigate the efficacy and adverse reactions of tenimoside (VM-26) combined with mid-dose cytarabine (Ara-C) in the treatment of refractory and recurrent acute leukemia. Methods Twenty two patients with refractory and relapsed acute leukemia were treated with intravenous infusion of teniposide for 1 ~ 3 days, Ara-C 0 .5 ~ 1.0gq 12h and days 1 ~ 3d. The curative effect and adverse reactions And follow-up. The results of complete remission in 10 cases, 45% complete remission; partial remission in 3 cases, partial remission rate of 13 6%; total effective rate of 586%. Sustained remission time of 3 to 12 months. The incidence of bone marrow suppression 10 0%. Conclusions VM-6 combined with mid-dose Ara-C is effective in refractory and relapsed acute leukemia, VM-6 is better than VP-16 and the dose of Ara-C is higher than Ara-C Smaller, most patients can tolerate.